Key Drivers
- Strong Liquidity
- Heavy Cash Burn
- Dilution Risk
AIAI Summary
ACRS is a well-funded but richly valued clinical-catalyst bet: its cash runway through 2028 reduces near-term distress, yet upside depends almost entirely on convincing ATI-052, bosakitug, and modzatinib data, while weak results or Phase 2b funding needs could drive sharp valuation compression and dilution.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Heavy Cash Burn
- •Dilution Risk
ACRS has strong debt-free liquidity but persistent heavy losses, cash burn, dilution risk, and extreme revenue/book valuation make the shares high risk.
Price Behavior
Key Price Behavior Insights:
- •Last-month decline
- •Support rebound
- •Resistance test
ACRS remains bearish over the last month, with a rebound from $5.32 offering support but a move above $5.64 needed to improve the outlook.
Rebound from $5.32 to $5.50 after a sharp decline
Sentiment & News
Key News Insights:
- •Deutsche Bank stake
- •High-volume rally
- •Cautious estimates
Deutsche Bank's $5.5M stake and a 6% high-volume rally boost Aclaris sentiment, though cautious earnings revisions may limit near-term upside.
The news is sentiment-positive but suggests upside may be constrained without stronger earnings momentum
Similar Companies in Healthcare
Other companies in the same sector with AI ratings